What Альбарел Treats: Main Uses and Benefits

Альбарел (Rilmenidine) is commonly used to provide long-term, stable management of mild to moderate essential hypertension (high blood pressure). This use focuses on the management of arterial hypertension to achieve a sustained reduction in blood pressure, which contributes to easing the overall symptom load on the heart and blood vessels.

This medication is relevant for easing the symptoms related to systemic imbalance by addressing the persistent elevation of systemic pressure readings. The core therapeutic use is relevant for managing conditions marked by increased physiological stress associated with cardiovascular risk. The drug is considered relevant for hypertensive patients who also face metabolic challenges, including Type 2 Diabetes or dyslipidemia. This use supports effective pressure control while assisting with the management of metabolic parameters.

“Provides support that helps ease the overall symptom burden, contributing to better day-to-day comfort and stability.”

Quick Fact: Relief for High Blood Pressure
Primary Condition	Essential Hypertension
Core Benefit	Sustained Pressure Reduction
Metabolic Relevance	Is commonly used for patients with diabetes or dyslipidemia

Regulatory References

1. EMA Rilmenidine therapeutic overview

Population Eligibility and Non-Eligibility for Альбарел

Альбарел (Rilmenidine) is intended for use in the adult population for the treatment of essential hypertension. The official regulatory profile defines clear boundaries for who may use the medicine and who must not, based on specific medical conditions, age, and physiological status.

Absolute Contraindications

Use of Rilmenidine is contraindicated (explicitly forbidden) in the following groups:

• Patients with severe depression.
• Individuals with known hypersensitivity to the active substance or any excipients.
• Patients with severe renal failure, defined by a creatinine clearance of less than 15 mL/min.

Restricted and Conditional Use

Use is not recommended for the pediatric population (children and adolescents) due to the absence of established safety and efficacy data. For women, the medicine is not recommended during lactation because Rilmenidine is excreted in breast milk, and its use should be avoided in pregnant women as a general precaution.

Patients with non-severe renal impairment (creatinine clearance greater than 15 mL/min) and diabetic hypertensive patients are generally permitted to use the medicine under established guidelines. However, patients with a recent history of cardiovascular disease (such as stroke or myocardial infarction) require regular medical monitoring.

Interactions with other medicines and products

Official regulatory information for Альбарел (Rilmenidine) details interaction patterns primarily governed by pharmacodynamic effects, which influence the drug’s primary action or introduce additive risks. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally not recommended due to the potential for severe outcomes, such as hypertensive crisis.

Documented Pharmacodynamic Effects

Co-administering Rilmenidine with other Antihypertensive Agents (e.g., diuretics, beta-blockers) may result in an enhanced blood pressure-lowering effect (additive hypotension). Similarly, an additive effect leading to enhanced sedation is documented when combined with Central Nervous System (CNS) Depressants or if consumed with alcohol, which should be officially avoided.

In contrast, the blood pressure-reducing efficacy of Rilmenidine may be reduced by co-administration with Tricyclic Antidepressants (TCAs) or certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), representing a pharmacodynamic antagonism. Furthermore, the use of Rilmenidine with Digitalis Glycosides is officially noted to increase the risk of bradycardia.

Specific herbal products (such as Garlic and Ginger) are identified in regulatory summaries as having the potential to alter effectiveness or contribute to an additive blood pressure-lowering effect. For patients with renal impairment, official information advises caution, though no mandatory timing or separation requirements are specified for Rilmenidine administration.

How Альбарел Works

---

Central Regulation via Imidazoline I1 Receptors

The primary mechanism of Rilmenidine is the selective activation (agonism) of Imidazoline I1 Receptors ( I1-IRs) found in the brainstem. This central suppression of activity initiates a cascade that reduces the amount of the vasoconstricting neurotransmitter, Norepinephrine, released peripherally. This decrease in sympathetic nerve signaling originates from the Rostral Ventrolateral Medulla (RVLM).

---

Modulating Vascular Tone and Resistance

The reduced release of Norepinephrine directly influences the blood vessels, causing the vascular smooth muscle to relax and leading to vasodilation (widening). This reduction in sympathetic drive and subsequent relaxation decreases the Total Peripheral Resistance, the force against which blood must be circulated. This is a primary physiological consequence that shapes the drug’s mechanistic profile.

---

Complementary Action on Renal Volume Control

In addition to the central effects, Rilmenidine also engages I1-IRs in the kidney, which leads to the inhibition of the Na^+/ H^+ antiport. This action limits the reabsorption of sodium and water in the renal tubules, promoting their excretion. This mechanism contributes to the adjustment of the body’s fluid balance, which functionally complements the drug’s central action on vascular resistance.

Administration Protocol

Альбарел (Rilmenidine) is intended for long-term oral administration, provided in tablet form. The use protocol prescribes the route, frequency, and conditions for consumption.

Dosing and Frequency

The standard protocol begins with a starting dose of 1 mg of Rilmenidine once daily. This initial dose is typically maintained for a minimum period of one month to assess stability before any dosage adjustment is considered. The maximum daily dose is 2 mg. When the maximum dose is administered, it is taken in divided portions, consisting of one 1 mg tablet in the morning and one 1 mg tablet in the evening.

Administration Conditions

For the standard 1 mg regimen, the tablet is generally administered as a single dose in the morning. When the 2 mg dose is utilized in two divided administrations, the tablets are taken before meals. The tablets must be swallowed whole with water and are not intended to be crushed or chewed.

Population-Specific Use

Administration rules address specific patient groups. For older adults, no dose adjustment is typically required, provided that kidney function remains within normal limits. Conversely, the use protocol requires dose limitation or modification for patients with significant impairment of renal function. The medication is not recommended for use in pediatric patients as this population lacks established dosing regimens.

Альбарел: Recent Clinical Evidence

1. Core Research for Essential Hypertension

The primary evidence for Rilmenidine (Альбарел) is derived from short-term randomized controlled trials (RCTs) and multicenter comparative studies involving adult patients with mild to moderate essential hypertension. Researchers examined outcomes related to systemic imbalance, primarily monitoring changes in systolic and diastolic blood pressure (BP) values over defined intervals. These initial controlled studies typically spanned 8 to 12 weeks. Data extending observation periods for up to 1 year relied on open-label extension studies, which followed participants after the initial controlled trial phase.

2. Evidence in Metabolic Conditions and Subgroups

Research has also explored the medicine's use in hypertensive patients facing comorbidities, such as Type 2 Diabetes mellitus, dyslipidemia, or features of Metabolic Syndrome. Outcomes monitored in these controlled trials and retrospective analyses included BP and parameters related to glucose and lipid metabolism. Studies also monitored specific end-organ markers, such as microalbuminuria and Left Ventricular Hypertrophy (LVH) measurements. Data for these specialized subgroups often relies on smaller sample sizes, indicating that certainty remains low regarding the measured metabolic parameters.

3. Key Research Gaps and Uncertainty

A significant limitation in the research is the absence of prospective, controlled, long-term studies specifically designed to assess major hard outcomes like cardiovascular events (e.g., stroke, heart attack) or overall mortality. The consistency of evidence for secondary outcomes (such as metabolic markers) varies across studies. Findings describe group patterns over the observed time, but the limited follow-up durations prevent determining whether an individual's outcome will be similar over many years.

Key Studies & References

1. PUBLIC ASSESSMENT REPORT Scientific Discussion RILMENIDINE WINTHROP 1 mg Tablet (Rilmenidine) FR/H/462/01/MR

Common questions about Альбарел (FAQ)

Q: Is Albarel a muscle relaxant (spasmolytic) or a painkiller?

Albarel is officially classified as a Centrally Acting Antihypertensive Agent. Its main therapeutic indication is the management of high blood pressure by affecting signals in the brain. It is not classified as a muscle relaxant or a general painkiller in its official regulatory documentation.

Q: Are there any serious side effects of Albarel that I should be aware of?

Official documentation highlights certain safety restrictions and warnings. For instance, the medication is strictly contraindicated (should not be used) in patients with severe depression. Additionally, regulatory guidelines emphasize that the dosage should be reduced gradually when discontinuing treatment to mitigate the risk of adverse events, such as a sharp rise in blood pressure.

Q: How quickly does Albarel start to work for abdominal pain?

Albarel is indicated for the treatment of high blood pressure, not for abdominal pain. According to pharmacokinetic data, the active ingredient reaches its maximum concentration in the blood within approximately 1.5 to 2 hours after an oral dose. This timeframe refers to the rate of absorption, rather than the onset of the therapeutic effect for blood pressure control.

Q: What is the difference between Albarel and other spasmolytic (muscle relaxant) medicines?

Albarel is primarily an antihypertensive agent, not a muscle relaxant. Its mechanism involves activating specific I1-receptors in the brainstem to lower blood pressure. This differs fundamentally from the way muscle relaxants work, as Albarel targets the central nervous system to reduce vascular tension.

Q: Does Albarel affect blood pressure?

Yes, Albarel is specifically an antihypertensive medicine. Its main therapeutic goal is the treatment of high blood pressure (arterial hypertension), meaning its action is directed toward lowering and stabilizing blood pressure.

Q: Is Albarel safe for older adults?

Official administration protocols state that dose adjustment is generally not required for older patients (aged 70 years and above), provided their kidney function remains within normal limits. However, continuous medical monitoring is advised.

Q: Is Albarel approved for use in children?

Albarel is not recommended for use in children and adolescents. Official regulatory bodies state that this restriction is due to the lack of established safety and efficacy data for the pediatric population.

Q: What should I do if I miss a dose of Albarel?

Official product information advises against taking a double dose to compensate for a missed one. If you realize you missed a dose, you should take it only if there is a sufficient time gap before the next scheduled dose. Specific instructions for a missed dose should be confirmed with a healthcare provider.

Q: When should I take Albarel — before or after eating?

The official guidance states the medicine is generally taken before meals. Specifically, when taking the maximum daily dose divided into two administrations, the tablets are to be taken before the morning and evening meals. Taking the medicine with food does not significantly affect how it is absorbed.

Q: Can I take Albarel with painkillers (such as paracetamol or ibuprofen)?

Official information indicates that taking Albarel alongside certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce the blood pressure-lowering effect of Albarel. No specific interaction is described for paracetamol (acetaminophen) in the official product information.

Q: Are there studies confirming Albarel’s effectiveness for Irritable Bowel Syndrome (IBS)?

Clinical studies and official regulatory documentation confirm the effectiveness of Albarel exclusively for the treatment of essential arterial hypertension (high blood pressure). There are no official data supporting its use for conditions like Irritable Bowel Syndrome (IBS).

Q: Does Albarel affect liver or kidney function?

The drug is primarily eliminated from the body by the kidneys. Severe kidney failure represents a strict contraindication for the use of Albarel. While liver impairment may affect the drug’s half-life, the official information does not detail effects on otherwise normal liver function.

Q: Is it true that Albarel is eliminated quickly from the body?

According to pharmacokinetic studies, the half-life of the active ingredient in Albarel (Rilmenidine) is approximately 8 hours in adults with normal kidney function. This indicates the rate at which the body processes and clears the drug.

Q: Can I have an allergy to the ingredients in Albarel?

The product is strictly contraindicated for use if a patient has a known hypersensitivity (allergy) to the active substance (Rilmenidine) or any other ingredients included in the tablet formulation.

Q: How long does the effect last after taking one dose of Albarel?

The official product information indicates that the antihypertensive effect of a therapeutic dose of Albarel lasts for 24 hours. This duration is consistent with the generally prescribed once-daily dosing regimen.

Q: Does taking Albarel for a long time lead to tolerance or physical dependence?

Official studies show that the drug’s concentration in the bloodstream remains stable during long-term treatment, even up to two years. This stability suggests that the drug does not lead to the development of tolerance (loss of effectiveness due to habituation).

Q: What lab tests are recommended while taking Albarel?

Continuous medical monitoring is advised during treatment. Specifically, official warnings recommend evaluating kidney function (creatinine clearance) for patients, particularly if they have existing kidney impairment, to ensure the appropriate management.

Q: Is there a difference in effectiveness between Albarel capsules and tablets?

Albarel is officially manufactured and regulated only in the form of oral tablets. Therefore, no comparative data or effectiveness claims exist for a capsule form of the medication in the official documentation.

Q: Can I take Albarel along with probiotics?

Official drug interaction documentation does not list any known interactions between Albarel and probiotics or other general dietary supplements.

Q: Is there a risk of withdrawal syndrome if I stop taking Albarel?

Yes, regulatory warnings advise that treatment must not be interrupted abruptly. To prevent the rebound phenomenon, the dosage should be reduced gradually over time, as stopping suddenly can cause a sharp, unwanted increase in blood pressure.

Q: Does Albarel affect the sexual health of men and women?

Yes, regulatory documentation lists sexual dysfunction as one of the common side effects reported by users of Albarel.

Q: How does Albarel affect blood sugar levels?

In clinical studies involving hypertensive patients who also had diabetes, Albarel was not associated with any negative impact on the metabolism of glucose (blood sugar) or lipids (fats).

Q: How does Albarel affect heart rhythm?

Common side effects include palpitations (a noticeable irregular or rapid heartbeat). Furthermore, official warnings note that combining Albarel with certain heart medications may increase the risk of bradycardia (abnormally slow heart rate).

Q: Can Albarel affect my ability to drive a car?

At therapeutic doses, no effect on alertness has been specifically identified in studies. However, since drowsiness is a common side effect, patients are advised to exercise caution when driving or operating machinery if they experience this effect.

Q: Do I need a dose adjustment if I have kidney failure?

Dose adjustment is not required if the creatinine clearance (a measure of kidney function) is ge 15 mL/min. However, if the clearance is lower than this value, the drug is contraindicated and should not be used.

Q: Can Albarel cause dizziness?

The official product information lists drowsiness and fatigue as common side effects. Although the specific term 'dizziness' may not be listed directly, these effects may be associated with feelings of lightheadedness or unsteadiness.

Storage and Stability

The official regulatory documentation for Альбарел (Rilmenidine 1 mg tablets) states that the medicine does not require any special temperature storage conditions. This indicates the product is stable when maintained at ambient room temperature, typically below 25 C or 30 C.

Storage Requirement	Official Wording
Temperature	No special temperature storage conditions
Packaging	Store in the original package
Child Safety	Keep out of the sight and reach of children

To ensure product quality is maintained until the expiration date, the tablets must be stored in their original blister packaging. No special handling or post-opening stability limits apply, as the product is an oral tablet.

Disposal Instructions

Unused or expired Альбарел must be disposed of in accordance with local requirements. The medicine should not be discarded via wastewater or household waste. Patients are advised to consult a pharmacist or local waste authority for proper collection and disposal.